XenoTherapeutics Wins American Burn Association's Burke/Yannas Bioengineering Paper Award for Research on Xeno-Skin™

April 4, 2019

Burn specialists at Massachusetts General Hospital (MGH) announced today they have successfully used live-cell, genetically engineered pig skin (xenograft) for the temporary closure of a burn wound. Through an FDA-cleared phase one clinical trial led by surgeon Jeremy Goverman, MD, of the MGH Sumner Redstone Burn Service, this procedure marks the first-time pig tissue derived from an animal with gene edits has been transplanted directly onto a human wound.

Contact Us

359 Newbury Street, 5th Floor Suite 526

Boston, MA 02115

617-939-7892

info@xenotherapeutics.org

Connect with us
SUBSCRIBE

Federal EIN Number: 81-1016095

© 2020 by XenoTherapeutics Foundation

  • Black Facebook Icon
  • Black Twitter Icon
  • LinkedIn